summit tirzepatide for HFPEF and Obesity - AHA 24 Late-Breaking Discussion: SUMMIT:

This launch builds on Omadas track record of clinical excellence, including a number of published outcomes that have been shown to outperform key real-world benchmarks

Novel glucagon-like peptide-1 analogue exhibits potency-driven G-protein biased agonism with promising effects on diabetes and diabetic dry eye syndrome

To conclude, MEDI4166 has been engineered to be a novel long acting GLP-1R agonist peptide with a reduced potency in fusion with an optimized neutralising anti-PCSK9 antibody to deliver glycaemic and weight control in combination with LDL-C lowering

First-line management includes 30g daily dietary fibre, 1.52 litres of fluid, regular physical activity, and establishing a consistent toilet routine

GLP-1 and GIP also have effects on the brain that influence appetite and satiety

It has been found to slow the progression of kidney disease and reduce the risk of kidney failure in individuals with type 2 diabetes